Cargando…

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Oncolytic virotherapy is an emerging strategy that uses replication-competent viruses to kill tumor cells. We have reported the oncolytic effects of TG6002, a recombinant oncolytic vaccinia virus, in preclinical human xenograft models and canine tumor explants. To assess the safety, biodistribution...

Descripción completa

Detalles Bibliográficos
Autores principales:	Béguin, Jérémy, Gantzer, Murielle, Farine, Isabelle, Foloppe, Johann, Klonjkowski, Bernard, Maurey, Christelle, Quéméneur, Éric, Erbs, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838210/ https://www.ncbi.nlm.nih.gov/pubmed/33500518 http://dx.doi.org/10.1038/s41598-021-81831-2

Ejemplares similares

Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
por: Béguin, Jérémy, et al.
Publicado: (2020)

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
por: Béguin, Jérémy, et al.
Publicado: (2023)

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
por: Béguin, Jérémy, et al.
Publicado: (2020)

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
por: Foloppe, Johann, et al.
Publicado: (2019)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
por: Heinrich, B, et al.
Publicado: (2017)

Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs
por: Béguin, Jérémy, et al.
Publicado: (2021)

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
por: Ricordel, Marine, et al.
Publicado: (2018)

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
por: Autio, Karoliina, et al.
Publicado: (2014)

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
por: Delaunay, Tiphaine, et al.
Publicado: (2020)

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
por: Fend, Laetitia, et al.
Publicado: (2015)

Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
por: Myers, Rachel, et al.
Publicado: (2016)

Cowpox Virus: A New and Armed Oncolytic Poxvirus
por: Ricordel, Marine, et al.
Publicado: (2017)

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
por: Kleinpeter, Patricia, et al.
Publicado: (2016)

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
por: Gallardo, Franck, et al.
Publicado: (2020)

A clinical trial investigating biodistribution and shedding of an oncolytic virus
por: Reale, Alberto, et al.
Publicado: (2019)

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1
por: Kleinpeter, Patricia, et al.
Publicado: (2019)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
por: Tosch, Caroline, et al.
Publicado: (2017)

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
por: Remy-Ziller, Christelle, et al.
Publicado: (2017)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
por: Truong, Cao-Sang, et al.
Publicado: (2022)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
por: Guo, Zong Sheng, et al.
Publicado: (2019)

Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
por: Lee, Hyun Ju, et al.
Publicado: (2011)

Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
por: Deng, Lili, et al.
Publicado: (2022)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
por: Liu, Liqiong, et al.
Publicado: (2022)

Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy
por: Pelin, Adrian, et al.
Publicado: (2019)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
por: Gentschev, Ivaylo, et al.
Publicado: (2012)

Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression
por: Kochneva, Galina, et al.
Publicado: (2014)

Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9
por: Deng, Lili, et al.
Publicado: (2017)

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
por: Hill, Claudia, et al.
Publicado: (2021)

Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development
por: Ho, Tiffany Y., et al.
Publicado: (2021)

Generation of a Novel Oncolytic Vaccinia Virus Using the IHD-W Strain
por: Shin, Jaeil, et al.
Publicado: (2021)

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
por: Samson, Adel, et al.
Publicado: (2022)

Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy
por: Gómez, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cf51rvtu4ump3aa869o65updf4